meta
|
evidence
COVID-19
Living systematic review and meta-analysis
adjuvant therapies
anti-inflammatoty and immuno-therapy
antiandrogenic
antiviral and associated therapy
control
Drugs for acid related disorders
miscellaneous
Oral antidiabetic drugs
Renin-angiotensin-system-acting agents
vaccines
mRNA vaccine
Comirnaty (tozinameran - Pfizer/BIONTECH)
CureVac
Spikevax (Moderna mRNA-1273 COVID-19 vaccine)
Vitamins
potential COVID-19 treatments
control
placebo
uncontrolled study
vaccines
Non replicating viral vector
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19)
All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
secondary prevention
patient subgroup...
adolescents (typically 12-15 years of age)
adults (typically between 18 and 65yr)
age >= 55 yr
age >= 65 yr
age >= 75 yr
alpha variant (B.1.1.7, UK)
any cancer
beta variant (B.1.351 / 501Y.V2, South Africa)
children
delta variant (B.1.617.2, Indian)
dialysis patients
elderly (typically over 65yr)
fully vaccinated
haematological cancers
kidney transplant recipients
obese
omicron variant BA.1 (B.1.1.529)
positive for SARS-Cov-2 at baseline
solid cancer
solid organ transplant recipients
subjects at risk
Studies
Mapping
Meta-analysis
Excluded
Study
Exclusion reasons
Remarks
Reference(s)
Empty list - no studies excluded